1
|
Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, González-Martin A, Gourley C, Leary A, Lorusso D, Banerjee S, Chiva L, Cibula D, Colombo N, Croce S, Eriksson AG, Falandry C, Fischerova D, Harter P, Joly F, Lazaro C, Lok C, Mahner S, Marmé F, Marth C, McCluggage WG, McNeish IA, Morice P, Nicum S, Oaknin A, Pérez-Fidalgo JA, Pignata S, Ramirez PT, Ray-Coquard I, Romero I, Scambia G, Sehouli J, Shapira-Frommer R, Sundar S, Tan DSP, Taskiran C, van Driel WJ, Vergote I, Planchamp F, Sessa C, Fagotti A. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol 2024; 35:248-266. [PMID: 38307807 DOI: 10.1016/j.annonc.2023.11.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Revised: 11/17/2023] [Accepted: 11/28/2023] [Indexed: 02/04/2024] Open
Abstract
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.
Collapse
Affiliation(s)
- J A Ledermann
- Department of Oncology, UCL Cancer Institute, University College London, London, UK.
| | - X Matias-Guiu
- CIBERONC, Madrid; Department of Pathology, Hospital Universitari Arnau de Vilanova, IRBLLEIDA, University of Lleida, Lleida; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain.
| | - F Amant
- Department of Gynaecologic Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; Department of Gynecology, Center for Gynecological Oncology Amsterdam, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - N Concin
- Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Innsbruck, Austria; Department of Gynaecology and Gynaecologic Oncology, Evang. Kliniken Essen-Mitte, Essen, Germany
| | - B Davidson
- Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - C Fotopoulou
- Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK
| | - A González-Martin
- Department of Medical Oncology and Program in Solid Tumours-Cima, Cancer Center Clínica Universidad de Navarra, Madrid, Spain
| | - C Gourley
- Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
| | - A Leary
- Department of Medicine, Institut Gustave Roussy, Villejuif, France
| | - D Lorusso
- Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; Department of Woman, Child and Public Health, Catholic University of Sacred Heart, Rome, Italy
| | - S Banerjee
- The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
| | - L Chiva
- Department of Gynaecology and Obstetrics, Cancer Center Clínica Universidad de Navarra, Navarra, Spain
| | - D Cibula
- Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - N Colombo
- Department of Gynecologic Oncology, Istituto Europeo di Oncologia IRCCS, Milan; Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
| | - S Croce
- Department of Biopathology, Bergonié Institut, Bordeaux, France
| | - A G Eriksson
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Gynecologic Oncology, Division of Cancer Medicine, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
| | - C Falandry
- Institute of Aging, Hospices Civils de Lyon, Lyon; CarMeN Laboratory, INSERM U1060/Université Lyon 1/INRAE U1397/Hospices Civils Lyon, Pierre-Bénite, France
| | - D Fischerova
- Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - P Harter
- Department of Gynaecology and Gynaecologic Oncology, Evang. Kliniken Essen-Mitte, Essen, Germany; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group, Germany
| | - F Joly
- GINECO Group, Department of Medical Oncology, Centre François-Baclesse, University of Caen Normandy, Caen, France
| | - C Lazaro
- Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL-CIBERONC), L'Hospitalet de Llobregat, Barcelona, Spain
| | - C Lok
- Department of Gynecology, Center for Gynecological Oncology Amsterdam, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - S Mahner
- Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group, Germany; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich
| | - F Marmé
- Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group, Germany; Department of Obstetrics and Gynecology, University Hospital Mannheim, Mannheim; Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - C Marth
- Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Innsbruck, Austria
| | - W G McCluggage
- Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK
| | - I A McNeish
- Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK
| | - P Morice
- Department of Gynecologic Surgery, Gustave Roussy Cancer Campus, Villejuif, France
| | - S Nicum
- Department of Oncology, UCL Cancer Institute, University College London, London, UK
| | - A Oaknin
- Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona
| | - J A Pérez-Fidalgo
- Department of Medical Oncology, Hospital Clínico Universitario - INCLIVA, CIBERONC, Valencia, Spain
| | - S Pignata
- Department of Urology and Gynecology, Istituto Nazionale Tumori di Napoli, IRCCS Fondazione Pascale, Napoli, Italy
| | - P T Ramirez
- Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, USA
| | - I Ray-Coquard
- Department of Medical Oncology, Centre Léon Bérard, University Claude Bernard, Lyon, France
| | - I Romero
- Department of Medical Oncology, Instituto Valenciano Oncologia, Valencia, Spain
| | - G Scambia
- Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; Department of Woman, Child and Public Health, Catholic University of Sacred Heart, Rome, Italy
| | - J Sehouli
- North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin; Department of Gynecology with Center for Oncological Surgery, Charité Berlin University of Medicine, Berlin, Germany
| | | | - S Sundar
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham; Pan Birmingham Gynaecological Cancer Centre, City Hospital, Birmingham, UK
| | - D S P Tan
- Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; National University of Singapore (NUS) Centre for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Cancer Science Institute, National University of Singapore, Singapore; Department of Haematology-Oncology, National University Cancer Institute Singapore, National University Hospital, Singapore, Singapore
| | - C Taskiran
- Department of Gynecologic Oncology, School of Medicine, Koç University, Istanbul, Turkey
| | - W J van Driel
- Department of Gynecology, Center for Gynecological Oncology Amsterdam, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - I Vergote
- Department of Gynaecologic Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
| | | | - C Sessa
- Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
| | - A Fagotti
- Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; Department of Woman, Child and Public Health, Catholic University of Sacred Heart, Rome, Italy.
| |
Collapse
|
2
|
Hasson SP, Ray-Coquard I, Marth C, Harter P. Surgery and HIPEC in relapse for all patients with ovarian cancer? ESMO Open 2023; 8:102052. [PMID: 37922687 PMCID: PMC10651446 DOI: 10.1016/j.esmoop.2023.102052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2023] Open
Affiliation(s)
- S P Hasson
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Gynaecology Unit, The Royal Marsden Foundation Trust, London, UK.
| | - I Ray-Coquard
- Centre Leon Bérard, Université Claude Bernard Lyon Est, Lyon, France
| | - C Marth
- Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria
| | - P Harter
- Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany
| |
Collapse
|
3
|
González-Martín A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, Ray-Coquard I, Tan DSP, Bellet E, Oaknin A, Ledermann JA. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34:833-848. [PMID: 37597580 DOI: 10.1016/j.annonc.2023.07.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 07/26/2023] [Accepted: 07/28/2023] [Indexed: 08/21/2023] Open
Affiliation(s)
- A González-Martín
- Department of Medical Oncology and Program in Solid Tumors Cima-Universidad de Navarra, Cancer Center Clínica Universidad de Navarra, Madrid and Pamplona, Spain
| | - P Harter
- Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany
| | - A Leary
- Department of Medical Oncology, Gustave Roussy Cancer Center, INSERM U981, Université Paris-Saclay, Paris, France
| | - D Lorusso
- Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome; Department of Woman, Child and Public Health, Catholic University of the Sacred Heart, Rome, Italy
| | - R E Miller
- Department of Medical Oncology, University College Hospital, London; Department of Medical Oncology, St Bartholomew's Hospital, London, UK
| | - B Pothuri
- Department of Obstetrics and Gynecology, Perlmutter Cancer Center, NYU Langone Health, New York University School of Medicine, New York, USA
| | - I Ray-Coquard
- Department of Medical Oncology, Centre Leon Bernard and Université Claude Bernard Lyon I, Lyon, France
| | - D S P Tan
- Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; National University of Singapore (NUS) Centre for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Cancer Science Institute, National University of Singapore, Singapore, Singapore; Department of Haematology-Oncology, National University Cancer Institute, National University Hospital, Singapore, Singapore
| | - E Bellet
- ACTO-Alleanza contro il Tumore Ovarico, Milan, Italy
| | - A Oaknin
- Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
| | - J A Ledermann
- Department of Oncology, UCL Cancer Institute, University College London, London, UK
| |
Collapse
|
4
|
Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martin A, Marth C, Nagao S, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Alia EMG, Bogner G, Yoshida H, Lefeuvre-Plesse C, Buderath P, Mosconi AM, Lortholary A, Burges A, Medioni J, El-Balat A, Rodrigues M, Park-Simon TW, Dubot C, Denschlag D, You B, Pujade-Lauraine E, Harter P. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol 2023:S0923-7534(23)00686-5. [PMID: 37211045 DOI: 10.1016/j.annonc.2023.05.005] [Citation(s) in RCA: 33] [Impact Index Per Article: 33.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 05/05/2023] [Accepted: 05/10/2023] [Indexed: 05/23/2023] Open
Abstract
BACKGROUND In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly diagnosed advanced ovarian cancer patients in clinical response after first-line platinum-based chemotherapy plus bevacizumab, irrespective of surgical status. Prespecified, exploratory analyses by molecular biomarker status showed substantial benefit in patients with a BRCA1/BRCA2 mutation (BRCAm) or homologous recombination deficiency (HRD; BRCAm and/or genomic instability). We report the prespecified final overall survival (OS) analysis, including analyses by HRD status. PATIENTS AND METHODS Patients were randomized 2:1 to olaparib (300 mg bid; up to 24 months) plus bevacizumab (15 mg/kg q3w; 15 months total) or placebo plus bevacizumab. Analysis of OS, a key secondary endpoint in hierarchical testing, was planned for ∼60% maturity or 3 years after the primary analysis. RESULTS After median follow-up of 61.7 and 61.9 months in the olaparib and placebo arms, respectively, median OS was 56.5 versus 51.6 months in the ITT (hazard ratio [HR]=0.92, 95% CI 0.76-1.12; P=0.4118). Subsequent poly(ADP-ribose) polymerase (PARP) inhibitor therapy was received by 105 (19.6%) olaparib patients versus 123 (45.7%) placebo patients. In the HRD-positive population, OS was longer with olaparib plus bevacizumab (HR=0.62, 95% CI 0.45-0.85; 5-year OS rate, 65.5% versus 48.4%); at 5 years, updated PFS also showed a higher proportion of olaparib plus bevacizumab patients without relapse (HR=0.41, 95% CI 0.32-0.54; 5-year PFS rate, 46.1% versus 19.2%). Myelodysplastic syndrome, acute myeloid leukemia, aplastic anemia, and new primary malignancy incidence remained low and balanced between arms. CONCLUSIONS Olaparib plus bevacizumab provided clinically meaningful OS improvement for first-line patients with HRD-positive ovarian cancer. These prespecified exploratory analyses demonstrated improvement despite a high proportion of patients in the placebo arm receiving PARP inhibitors post-progression, confirming the combination as one of the standards of care in this setting with the potential to enhance cure.
Collapse
Affiliation(s)
- I Ray-Coquard
- Department of Medical Oncology, Centre Léon BERARD, Lyon, and GINECO, France;.
| | - A Leary
- Gynecological Cancer Unit, Department of Medicine, Institut Gustave Roussy, Villejuif, and GINECO, France
| | - S Pignata
- Department of Urology and Gynecology, Istituto Nazionale Tumori 'Fondazione G Pascale', IRCCS, Napoli, and MITO, Italy
| | - C Cropet
- Department of Biostatistics Centre Léon BERARD, Lyon, and GINECO, France
| | - A González-Martin
- Department of Medical Oncology, Clínica Universidad de Navarra, Program in Solid Tumors (CIMA), Pamplona, and GEICO, Spain
| | - C Marth
- Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, and AGO Austria, Austria
| | - S Nagao
- Department of Gynecologic Oncology, Hyogo Cancer Center, Akashi, and GOTIC, Japan
| | - I Vergote
- Department of Obstetrics and Gynaecology, University Hospital Leuven, Leuven Cancer Institute, Leuven, and BGOG, Belgium, European Union
| | - N Colombo
- University of Milan-Bicocca and Istituto Europeo di Oncologia IRCCS Milan, and MANGO, Italy
| | - J Mäenpää
- Department of Obstetrics and Gynecology and Cancer Center, Tampere University and University Hospital, Tampere, and NSGO, Finland
| | - F Selle
- Department of Medical Oncology, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, and GINECO, France
| | - J Sehouli
- Charité - Department of Gynecology with Center of Oncological Surgery, Universitätsmedizin Berlin, Berlin, and AGO, Germany
| | - D Lorusso
- (3)Gynecologic Oncology Unit, Catholic University of Sacred Heart and Fondazione Policlinico Gemelli IRCCS, Rome, and MITO, Italy
| | - E M Guerra Alia
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, and GEICO, Spain
| | - G Bogner
- Department of Obstetrics and Gynecology, Paracelsus Medical University Salzburg, Salzburg, and AGO Austria, Austria
| | - H Yoshida
- Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, and GOTIC, Japan
| | - C Lefeuvre-Plesse
- Department of Medical Oncology, Centre Eugène Marquis, Rennes, and GINECO, France
| | - P Buderath
- Universitätsklinikum Essen, University Hospital Essen, West German Cancer Center, Department of Gynecology and Obstetrics, Essen and AGO, Germany
| | - A M Mosconi
- S.C. di Oncologia Medica Osp. S. Maria della Misericordia - AO di Perugia, and MITO, Italy
| | - A Lortholary
- Centre Catherine de Sienne Hopital privé du Confluent, Nantes, and GINECO, France
| | - A Burges
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, and AGO, Germany
| | - J Medioni
- Hôpital Européen Georges Pompidou, Universite de Paris Cite, Paris, and GINECO, France
| | - A El-Balat
- Spital Uster, Frauenklinik, Uster, Switzerland, and Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, and AGO, Germany
| | - M Rodrigues
- Department of Medical Oncology, Institut Curie, Hopital Claudius Régaud, PSL Research University, Paris, France, and GINECO, France
| | - T-W Park-Simon
- Department of Gynaecology and Obstetrics, Hannover Medical School, Hannover, and AGO, Germany
| | - C Dubot
- Oncologie Médicale, Institut Curie, Hôpital René Huguenin, Saint Cloud, Paris, and GINECO, France
| | - D Denschlag
- Hochtaunuskliniken, Bad Homburg, and AGO, Germany
| | - B You
- HCL - Hospices Civils de Lyon IC-HCL, CITOHL, Université Claude Bernard Lyon 1, CICLY,Lyon, and GINECO, France
| | | | - P Harter
- Department of Gynaecology & Gynaecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, and AGO, Germany
| |
Collapse
|
5
|
Bossart M, Plett H, Krämer B, Braicu E, Czogalla B, Klar M, Singer S, Mayr D, Staebler A, du Bois A, Kommoss S, Link T, Burges A, Heitz F, Grube M, Trillsch F, Harter P, Wimberger P, Buderath P, Hasenburg A. Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT database. Arch Gynecol Obstet 2023; 307:1155-1162. [PMID: 36127525 PMCID: PMC10023613 DOI: 10.1007/s00404-022-06781-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Accepted: 08/31/2022] [Indexed: 11/12/2022]
Abstract
INTRODUCTION The intention of this study was to evaluate the level of anxiety and depression of malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST) survivors and to identify possible alterable cofactors. METHODS CORSETT was an observational, multicenter, mixed retrospective/prospective cohort study of the AGO Studygroup. Women who had been diagnosed with MOGCTs and SCSTs between 2001 and 2011 were asked to complete the Hospital Anxiety and Depression Scale (HADS) to evaluate distress. Predictors of distress (type of surgery, chemotherapy, time since diagnosis, recurrence, second tumor, pain) were investigated using multivariate linear regression analysis. RESULTS 150 MOGCT and SCST patients with confirmed histological diagnosis completed the questionnaire median seven years after diagnosis. They had a HADS total score ≥ 13 indicating severe mental distress in 34% of cases. Patients after fertility-conserving surgery had lower probability of severe mental distress than those without fertility-conserving treatment (β = - 3.1, p = 0.04). Pain was associated with the level of distress in uni- and multivariate analysis (coef 0.1, p < 0.01, coef. Beta 0.5). DISCUSSION Severe mental distress was frequent in patients with MOGCT and SCST and the level of pain was associated with the level of distress. Fertility conserving therapy, however, was associated with less mental distress. Screening and treatment of pain and depression is required to improve mental well-being in survivors of MOGCT and SCST.
Collapse
Affiliation(s)
- M Bossart
- Department of Gynecology and Obstetrics, University Medical Center Freiburg, Freiburg im Breisgau, Germany.
- Department of Gynecology and Obstetrics, St. Josefskrankenhaus Freiburg, Freiburg im Breisgau, Germany.
| | - H Plett
- Department of Gynecology & Gynecologic Oncology, Ev. Kliniken Essen-Mitte (KEM), Essen, Germany
| | - B Krämer
- Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany
| | - E Braicu
- Department of Gynecology, Charité Berlin, Campus Virchow Clinic, Berlin, Germany
| | - B Czogalla
- Department of Obstetrics and Gynecology, University Hospital, Ludwig- Maximilians- University Munich, Munich, Germany
| | - M Klar
- Department of Gynecology and Obstetrics, University Medical Center Freiburg, Freiburg im Breisgau, Germany
| | - S Singer
- Institute of Medical Biostatistics, Epidemiology and Informatics, Division of Epidemiology and Health Care Research, University Medical Center Mainz, Mainz, Germany
- Department of Gynecology and Obstetrics, University Medical Center Mainz, Mainz, Germany
| | - D Mayr
- Institut of Pathology, Ludwig-Maximilians- University Munich, Munich, Germany
| | - A Staebler
- Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University of Tuebingen, Tuebingen, Germany
| | - A du Bois
- Department of Gynecology & Gynecologic Oncology, Ev. Kliniken Essen-Mitte (KEM), Essen, Germany
| | - S Kommoss
- Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany
| | - T Link
- Department of Gynecology and Obstetrics, Technische Universität Dresden Dresden and National Center for Tumor Diseases (NCT/UCC), Dresden, Germany
| | - A Burges
- Department of Obstetrics and Gynecology, University Hospital, Ludwig- Maximilians- University Munich, Munich, Germany
| | - F Heitz
- Department of Gynecology & Gynecologic Oncology, Ev. Kliniken Essen-Mitte (KEM), Essen, Germany
| | - M Grube
- Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany
| | - F Trillsch
- Department of Obstetrics and Gynecology, University Hospital, Ludwig- Maximilians- University Munich, Munich, Germany
| | - P Harter
- Department of Gynecology & Gynecologic Oncology, Ev. Kliniken Essen-Mitte (KEM), Essen, Germany
| | - P Wimberger
- Department of Gynecology and Obstetrics, Technische Universität Dresden Dresden and National Center for Tumor Diseases (NCT/UCC), Dresden, Germany
| | - P Buderath
- Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany
| | - A Hasenburg
- Department of Gynecology and Obstetrics, University Medical Center Mainz, Mainz, Germany
| |
Collapse
|
6
|
Boidot R, Blum M, Wissler MP, Gottin C, Ruzicka J, Duforet-Frebourg N, Jeanniard A, Just PA, Harter P, Pignata S, Gonzalez Martin A, Marth C, Mäenpää J, Colombo N, Vergote I, Fujiwara K, Bertrand D, Philippe N, Ray-Coquard I, Pujade-Lauraine E. 39MO Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.100819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023] Open
|
7
|
Lorusso D, Mouret-Reynier MA, Harter P, Cropet C, Caballero Diaz C, Petru E, Satoh T, Vergote I, Parma G, Jakobi Nøttrup T, Lebreton C, Fasching P, Pisano C, Manso L, Bourgeois H, Runnebaum I, Hardy-Bessard AC, Schnelzer A, Pujade-Lauraine E, Ray-Coquard I. 32O 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.100812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023] Open
|
8
|
Matulonis U, Moore K, Lorusso D, Oaknin A, Pignata S, Denys H, Colombo N, Van Gorp T, Konner J, Romeo Marin M, Harter P, Murphy C, Tu Y, Zhu F, Esteves B, Method M, Birrer M, Coleman R, O'Malley D. 592P Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
9
|
Lecuru F, Sehouli J, Vergote I, Reuss A, Classe JM, Hillemanns P, Greggi S, Mirza M, Brachet P, Follana P, Raban N, Hasenburg A, Zang R, Lindemann K, Kim JW, Poveda A, Raspagliesi F, Haslund C, du Bois A, Harter P. 573P Role of CA125 in patients included in the DESKTOP III/ENGOT-ov20 trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
10
|
Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, Lorusso D, Marth C, Makker V, Mirza MR, Ledermann JA, Colombo N. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33:860-877. [PMID: 35690222 DOI: 10.1016/j.annonc.2022.05.009] [Citation(s) in RCA: 123] [Impact Index Per Article: 61.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Revised: 04/27/2022] [Accepted: 05/19/2022] [Indexed: 12/24/2022] Open
Affiliation(s)
- A Oaknin
- Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
| | - T J Bosse
- Departments of Pathology, Leiden University Medical Center, Leiden, The Netherlands
| | - C L Creutzberg
- Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands
| | - G Giornelli
- Department of Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina
| | - P Harter
- Department of Gynecology & Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany
| | - F Joly
- ANTICIPE, Cancer and Cognition Platform, Normandie University, Caen, France; Medical Oncology Department, Centre François Baclesse, Caen, France
| | - D Lorusso
- Department of Life Science and Public Health, Catholic University of Sacred Heart, Largo Agostino Gemelli, Rome, Italy; Department of Women and Child Health, Division of Gynaecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | - C Marth
- Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria
| | - V Makker
- Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, USA
| | - M R Mirza
- Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - J A Ledermann
- Cancer Institute, University College London (UCL), London, UK; Department of Oncology, UCL Hospitals, London, UK
| | - N Colombo
- Department of Gynecologic Oncology, Istituto Europeo di Oncologia IRCCS, Milan, Italy; Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
| |
Collapse
|
11
|
Holly J, Harter P, Ataseven B, Moubarak M, Schwameis R, Heikaus S, Concin N, Rhiem K, Denkert C, Heitz F. HRD-Testung und BRCA1/2-Keimbahntestung in der
klinischen Routine bei Patientinnen mit primärem
Ovarialkarzinom. Geburtshilfe Frauenheilkd 2022. [DOI: 10.1055/s-0042-1746158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- J Holly
- Evangelische Kliniken Essen Mitte, Klinik für
Gynäkologie und Gynäkologische Onkologie, Essen,
Deutschland
| | - P Harter
- Evangelische Kliniken Essen Mitte, Klinik für
Gynäkologie und Gynäkologische Onkologie, Essen,
Deutschland
| | - B Ataseven
- Evangelische Kliniken Essen Mitte, Klinik für
Gynäkologie und Gynäkologische Onkologie, Essen,
Deutschland
- Abteilung für Geburtshilfe und Gynäkologie,
Universitätsklinikum, LMU München, Deutschland
| | - M Moubarak
- Evangelische Kliniken Essen Mitte, Klinik für
Gynäkologie und Gynäkologische Onkologie, Essen,
Deutschland
| | - R Schwameis
- Evangelische Kliniken Essen Mitte, Klinik für
Gynäkologie und Gynäkologische Onkologie, Essen,
Deutschland
- Abteilung für allgemeine Gynäkologie und
gynäkologische Onkologie, Universitätsklinik für
Frauenheilkunde, MedUni Wien, Österreich
| | - S Heikaus
- Evangelische Kliniken Essen Mitte, Zentrum für Pathologie,
Essen, Deutschland
| | - N Concin
- Evangelische Kliniken Essen Mitte, Klinik für
Gynäkologie und Gynäkologische Onkologie, Essen,
Deutschland
- Universitätsklinik für Frauenheilkunde, MedUni
Innsbruck, Österreich
| | - K Rhiem
- Zentrum Familiärer Brust- und Eierstockkrebs der
Universitätsklinik Köln, Deutschland
| | - C Denkert
- Institut für Pathologie, Philipps-Universität Marburg
und Universitätsklinik Marburg (UK-GM) Deutschland)
| | - F Heitz
- Evangelische Kliniken Essen Mitte, Klinik für
Gynäkologie und Gynäkologische Onkologie, Essen,
Deutschland
- Klinik für Gynäkologie mit dem Center für
Onkologische Operative Therapie, Charité Campus, Virchowklinikum,
Charité- Universitätsmedizin Berlin, Freie Universität
Berlin, Humboldt Universität zu Berlin, Berlin Institut of Health,
Deutschland
| |
Collapse
|
12
|
Vergote I, González-Martín A, Ray-Coquard I, Harter P, Colombo N, Pujol P, Lorusso D, Mirza MR, Brasiuniene B, Madry R, Brenton JD, Ausems MGEM, Büttner R, Lambrechts D. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol 2022; 33:276-287. [PMID: 34861371 DOI: 10.1016/j.annonc.2021.11.013] [Citation(s) in RCA: 54] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Revised: 11/18/2021] [Accepted: 11/22/2021] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade serous ovarian carcinomas. Ovarian cancers harbouring HRR deficiency typically exhibit sensitivity to poly-ADP ribose polymerase inhibitors (PARPi). Current guidelines recommend a range of approaches for genetic testing to identify predictors of sensitivity to PARPi in ovarian cancer and to identify genetic predisposition. DESIGN To establish a European-wide consensus for genetic testing (including the genetic care pathway), decision making and clinical management of patients with recently diagnosed advanced ovarian cancer, and the validity of biomarkers to predict the effectiveness of PARPi in the first-line setting. The collaborative European experts' consensus group consisted of a steering committee (n = 14) and contributors (n = 84). A (modified) Delphi process was used to establish consensus statements based on a systematic literature search, conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. RESULTS A consensus was reached on 34 statements amongst 98 caregivers (including oncologists, pathologists, clinical geneticists, genetic researchers, and patient advocates). The statements concentrated on (i) the value of testing for BRCA1/2 mutations and HRR deficiency testing, including when and whom to test; (ii) the importance of developing new and better HRR deficiency tests; (iii) the importance of germline non-BRCA HRR and mismatch repair gene mutations for predicting familial risk, but not for predicting sensitivity to PARPi, in the first-line setting; (iv) who should be able to inform patients about genetic testing, and what training and education should these caregivers receive. CONCLUSION These consensus recommendations, from a multidisciplinary panel of experts from across Europe, provide clear guidance on the use of BRCA and HRR deficiency testing for recently diagnosed patients with advanced ovarian cancer.
Collapse
Affiliation(s)
- I Vergote
- Division of Gynaecological Oncology, Department of Gynaecology and Obstetrics and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
| | - A González-Martín
- Clinica Universidad de Navarra, Madrid, Spain; Program for Solid Tumors at Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain
| | - I Ray-Coquard
- Medical Oncology, Centre Leon Bérard and Université Claude Bernard Lyon, Lyon, France
| | - P Harter
- Department of Gynaecology & Gynaecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany
| | - N Colombo
- University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan, Italy
| | - P Pujol
- Montpellier Faculty of Medicine, University Hospital of Montpellier, Montpellier, France
| | - D Lorusso
- Department of Women and Child Science and Public Health, Catholic University of Rome, Fondazione Policlinico Gemelli IRCCS, Rome, Italy
| | - M R Mirza
- Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - B Brasiuniene
- Department of Medical Oncology, National Cancer Institute of Lithuania, Faculty of Medicine of Vilnius University, Vilnius, Lithuania
| | - R Madry
- Oncological Gynaecology Department, Poznan University of Medical Sciences, Poznan, Poland
| | - J D Brenton
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - M G E M Ausems
- Division Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
| | - R Büttner
- Institute of Pathology, University Hospital Cologne, Cologne, Germany
| | - D Lambrechts
- Department of Human Genetics, VIB and KU Leuven, Leuven, Belgium
| |
Collapse
|
13
|
Armbrust R, Richter R, Woopen H, Hilpert F, Harter P, Sehouli J. Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients. ESMO Open 2021; 6:100081. [PMID: 33743329 PMCID: PMC8010392 DOI: 10.1016/j.esmoop.2021.100081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Revised: 01/11/2021] [Accepted: 01/30/2021] [Indexed: 11/18/2022] Open
Abstract
Objective Recurrent ovarian cancer is an incurable disease with variable but poor prognosis. Health-related quality of life (HRQoL) is a patient-reported outcome measure generally applied to measure effects of therapies. Our aim was the development and validation of a risk score for the prediction of short-term mortality using the combination of sociodemographic and clinical factors and HRQoL. Methods For exploratory and validation analysis, the North-Eastern German Society of Gynecological Oncology (NOGGO) and Working Group Gynecological Oncology (AGO) study databases were screened for trials. Only trials which obtained defined HRQoL measurements were included in the final analysis. Multivariable logistic regression analyses were used to identify risk factors and their weighting for the risk score. Modulation with cubic regression analyses revealed median survival and short-term mortality defined as 1-year mortality for each value. Results For exploration, 974 patients from three clinical studies of the NOGGO and for validation, 1235 patients from several clinical studies of the AGO were eligible. The risk score included platinum-free interval, performance status, age, global QoL and nausea/vomiting. Receiver operating characteristic analysis showed a good predictive value with an area under the curve of 0.81 for model 1 in the exploration and 0.74 in the validation. Short-term mortality in model 1 was 8.2%, 23.5% and 58.4% in the exploration sample, and 19.7%, 38.1% and 63.4% in the validation sample for patients under low, medium and high risk, respectively. Conclusions This risk score discriminates well between recurrent ovarian cancer patients under low, medium and high risk of short-term mortality. It may help to identify a risk group under high risk for short-term mortality that can be used for randomization in clinical trials and may support decision making for palliative chemotherapy. This newly developed NOGGO-AGO QoL prognosis score clearly discriminates recurrent ovarian cancer (rOC) patients under low, medium and high risk for short-term survival (<1 year). The risk score included platinum-free interval, performance status, age, global QoL and nausea/vomiting. NOGGO-AGO QoL score can be used for stratification or randomization in clinical trials and for identification of a group under high risk for short-term mortality. It may also help the decision making for chemotherapy and provide more precise information of further life expectation for rOC patients.
Collapse
Affiliation(s)
- R Armbrust
- Department of Gynecology with Center for Oncological Surgery, Virchow Campus Clinic, Charité Medical University, Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany
| | - R Richter
- Department of Gynecology with Center for Oncological Surgery, Virchow Campus Clinic, Charité Medical University, Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany
| | - H Woopen
- Department of Gynecology with Center for Oncological Surgery, Virchow Campus Clinic, Charité Medical University, Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany
| | - F Hilpert
- Department of Gynecology, Krankenhaus Jerusalem Hamburg, Hamburg, Germany
| | - P Harter
- Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany
| | - J Sehouli
- Department of Gynecology with Center for Oncological Surgery, Virchow Campus Clinic, Charité Medical University, Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
| |
Collapse
|
14
|
Fujiwara K, Fujiwara H, Yoshida H, Satoh T, Yonemori K, Nagao S, Matsumoto T, Kobayashi H, Bourgeois H, Harter P, Mosconi A, Palacio I, Reinthaller A, Fujita T, Bloomfield R, Pujade-Lauraine E, Ray-Coquard I. 236O Olaparib (ola) plus bevacizumab (bev) as maintenance (mx) therapy in patients (pts) with newly diagnosed advanced ovarian carcinoma (OC): Japan subset of the PAOLA-1 trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
15
|
Tripon D, Harter P, Rhiem K, Schneider S, du Bois A, Heitz F, Baert T, Traut A, Pauly N, Ehmann S, Schmutzler R, Ataseven B. Prävalenz von BRCA1 and BRCA2 Mutationen bei Patientinnen mit primärem Ovarialkarzinom – Bildet die deutsche Checkliste zur Erfassung des Risikos für familiären Brust-/und Eierstockkrebs den Beratungsbedarf ausreichend ab? Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- D Tripon
- Kliniken Essen-Mitte
- LMU Klinik für Frauenheilkunde und Geburtshilfe
| | | | - K Rhiem
- Zentrum Familiärer Brust- und Eierstockkrebs
| | | | | | - F Heitz
- Kliniken Essen-Mitte
- Charite Berlin, Gynäkologie
| | - T Baert
- Kliniken Essen-Mitte
- Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, ImmunOvar Research Group
| | | | | | | | | | - B Ataseven
- Kliniken Essen-Mitte
- LMU Klinik für Frauenheilkunde und Geburtshilfe
| |
Collapse
|
16
|
Woelber L, Bommert M, Harter P, Prieske K, zu Eulenburg C, Jueckstock J, Hilpert F, de Gregorio N, Iborra S, Sehouli J, Ignatov A, Hillemanns P, Fuerst S, Strauss HG, Baumann K, Thiel F, Mustea A, Meier W, Wimberger P, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Mahner S, Jaeger A. Role of pelvic lymph node resection in vulvar cancer – a subset analysis of the AGO-CaRE-1 study. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- L Woelber
- Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf
| | | | | | - K Prieske
- Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf
| | - C zu Eulenburg
- Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf
| | - J Jueckstock
- Department of Gynecology and Obstetrics, University of Munich
| | - F Hilpert
- Oncologic Medical Center at the Jerusalem Hospital Hamburg
| | - N de Gregorio
- Department of Obstetrics and Gynecology, University of Ulm Medical Center
| | - S Iborra
- Gynecology and Gynecologic Oncology, University Hospital Freiburg
| | - J Sehouli
- Department of Gynecology, Charité University Medicine Berlin, Campus Virchow
| | - A Ignatov
- Department of Obstetrics and Gynecology, University Hospital Magdeburg
| | - P Hillemanns
- Department of Obstetrics and Gynecology, Hannover Medical School
| | - S Fuerst
- Department of Gynecology and Obstetrics, University of Munich
| | - HG Strauss
- Department of Gynecology, University Hospital Halle
| | - K Baumann
- Department of Gynecology, Medical Center Ludwigshafen
| | - F Thiel
- Department of Gynecology, Medical Center am Eichert, Alb Fils Clinic, Klinik am Eichert
| | - A Mustea
- Department of Gynecology and Gynecologic Oncology, University Medical Center Bonn
| | - W Meier
- Department of Obstetrics and Gynecology, Evangelical Hospital Duesseldorf
| | - P Wimberger
- Department of Gynecology and Gynecologic Oncology, Technical University Medical Center Dresden
| | - L Hanker
- Department of Gynecology and Gynecologic Oncology, University Medical Center Luebeck
| | - B Schmalfeldt
- Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf
| | - U Canzler
- Department of Gynecology and Gynecologic Oncology, Technical University Medical Center Dresden
| | - T Fehm
- Department of Obstetrics and Gynecology, Evangelical Hospital Duesseldorf
| | - A Luyten
- Department of Gynecology and Obstetrics, Medical Center Wolfsburg
| | - M Hellriegel
- Department of Gynecology and Gynecologic Oncology, University Medical Center Goettingen
| | - J Kosse
- Department of Gynecology and Obstetrics, Medical Center Offenbach
| | - C Heiss
- Department of Gynecology, Medical Center am Eichert, Alb Fils Clinic, Klinik am Eichert
| | - P Hantschmann
- Department of Gynecology and Obstetrics, Medical Center Altoetting
| | - P Mallmann
- Department of Gynecology and Gynecologic Oncology, University Medical Center Koeln
| | - B Tanner
- Department of Gynecology and Obstetrics, Medical Center Oranienburg
| | - J Pfisterer
- Department of Gynecology and Gynecologic Oncology, University Medical Center Kiel
| | - S Mahner
- Department of Gynecology and Obstetrics, University of Munich
| | - A Jaeger
- Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf
| |
Collapse
|
17
|
Pauly N, du Bois A, Harter P, Baert T, Heitz F, Schneider S, Heikaus S, Traut A, Ehmann S, Ataseven B. Welchen Mehrwert bringt eine zusätzliche Bestimmung molekularpathologischer, immunhistochemischer Parameter zusätzlich zur konventionellen histopathologischen Evaluation des frühen Endometriumkarzinoms? Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
| | | | | | - T Baert
- Kliniken Essen-Mitte
- Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven
| | - F Heitz
- Kliniken Essen-Mitte
- Charité – Universitätsmedizin Berlin
| | | | | | | | | | - B Ataseven
- Kliniken Essen-Mitte
- LMU Klinik für Frauenheilkunde und Geburtshilfe
| |
Collapse
|
18
|
Prieske K, Woelber L, Muallem M, Eulenburg C, Jückstock J, Hilpert F, de Gregorio N, Iborra S, Ignatov A, Hillemanns P, Fuerst S, Strauss H, Baumann K, Thiel F, Mustea A, Meier W, Harter P, Wimberger P, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Sehouli J, Mahner S. The influence of age on treatment and prognosis of patients with squamous cell vulvar cancer (VSCC)- a subset analysis of the AGO-CaRE-1 study. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- K Prieske
- Universitätklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie
| | - L Woelber
- Universitätklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie
| | - M.Z Muallem
- Charité, Campus Virchow Klinikum, Frauenklinik
| | - C Eulenburg
- Universitätklinikum Hamburg-Eppendorf, Institut für medizinische Biometrie und Epidemiologie
| | - J Jückstock
- Klinikum der Ludwig-Maximilians-Universität München, Campus Großhadern& Campus Innenstadt, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - F Hilpert
- Onkologisches Therapiezentrum am Jerusalem Krankenhaus
| | | | - S Iborra
- Uniklinik RWTH Aachen, Klinik für Gynäkologie und Geburtsmedizin
- Universitätsklinikum Freiburg, Universitäts- Frauenklinik
| | - A Ignatov
- Universitätsklinikum Magdeburg, Frauenklinik
| | | | - S.T Fuerst
- Klinikum der Ludwig-Maximilians-Universität München, Campus Großhadern& Campus Innenstadt, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - H.G Strauss
- Universitätsklinikum Martin-Luther-Universität Halle-Wittenberg
| | | | - F Thiel
- Alb Fils Kliniken, Klinik am Eichert, Frauenklinik
| | - A Mustea
- Universitätsklinikum Bonn, Klinik für Gynäkologie und Gynäkologische Onkologie
| | - W Meier
- Evangelisches Krankenhaus, Frauenklinik
| | - P Harter
- Kliniken Essen-Mitte (KEM) Evang. Huyssens-Stiftung/Knappschaft GmbH, Klinik für Gynäkologie und gynäkologische Onkologie
| | - P Wimberger
- Technische Universität Dresden, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - L Hanker
- Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe
| | - B Schmalfeldt
- Universitätklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie
| | - U Canzler
- Technische Universität Dresden, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - T Fehm
- Universitätsklinikum Düsseldorf, Universitätsfrauenklinik
| | - A Luyten
- Klinikum Wolfsburg, Frauenklinik
- Dysplasie-Einheit an der Park-Klinik Kiel
| | - M Hellriegel
- Georg-August-Universitätsklinikum Göttingen, Universitäts-Frauenklinik
| | - J Kosse
- Sana Klinikum Offenbach, Frauenklinik
| | - C Heiss
- Alb Fils Kliniken, Klinik am Eichert, Frauenklinik
| | | | - P Mallmann
- Klinikum der Universität zu Köln, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| | - B Tanner
- Oberhavel Kliniken, Klinik Oranienburg, Frauenklinik
| | | | - J Sehouli
- Charité, Campus Virchow Klinikum, Frauenklinik
| | - S Mahner
- Klinikum der Ludwig-Maximilians-Universität München, Campus Großhadern& Campus Innenstadt, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
| |
Collapse
|
19
|
Ehmann S, Ramspott J, du Bois A, Harter P, Heitz F, Schneider S, Baert T, Pauly N, Traut A, Heikaus S, Ataseven B. Histopathologisches Resultat nach prophylaktischer bilateraler Salpingo-Oophorektomie bei Frauen mit BRCA1/2-Mutation – single center Erfahrung. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
| | | | | | | | | | | | - T Baert
- Kliniken Essen-Mitte
- ImmunOvar Research Group, Laboratory of Tumor Immunology and Immunotherapy, Department of Oncology, KU Leuven
| | | | | | | | - B Ataseven
- Kliniken Essen-Mitte
- LMU Klinik für Frauenheilkunde und Geburtshilfe
| |
Collapse
|
20
|
JP R, ML M, AK L, Traut A, Ataseven B, Bommert M, Heitz F, Prader S, Schneider S, KU W, Heikaus S, Harter P, du Bois A, Baert T. Chemotherapy Response Score: Correlation with preoperative assessment of serological response and clinical implications in ovarian cancer patients. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- Ramspott JP
- Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology
| | - MacKintosh ML
- St Mary’s Hospital, Manchester University Hospitals NHS Trust, Gynaecological Oncology
| | | | - A Traut
- Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology
| | - B Ataseven
- Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology
- LMU Klinik für Frauenheilkunde und Geburtshilfe
| | - M Bommert
- Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology
| | - F Heitz
- Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology
| | - S Prader
- Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology
| | - S Schneider
- Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology
| | | | | | - P Harter
- Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology
| | - A du Bois
- Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology
| | - T Baert
- Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology
- Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven
| |
Collapse
|
21
|
Hilpert F, du Bois A, Pfisterer J, Sehouli J, Lamparter C, Kerkmann M, Harter P. Steigerung der Therapiequalität des Ovarialkarzinoms in Deutschland – Ergebnisse der eigenverantwortlichen QS Ovar. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
| | - A du Bois
- Kliniken Essen-Mitte, Gynäkologie und Gynäkologische Onkologie
| | | | - J Sehouli
- Charité Universitätsmedizin Berlin, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie (CVK) und Klinik für Gynäkologie (CBF
| | | | | | - P Harter
- Kliniken Essen-Mitte, Klinik für Gynäkologie und Gynäkologische Onkologie
| |
Collapse
|
22
|
Yazdian M, Ataseven B, Schneider S, Baert T, Bommert M, Traut A, du Bois A, Harter P. The role of factor (f) XIII in patients with advanced epithelial ovarian cancer (EOC) FIGO III/IV. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Yazdian
- Kliniken Essen-Mitte (KEM) Evang. Huyssens-Stiftung/Knappschaft GmbH, Gynäkologische Onkologie
- Frauenklinik Universität Marburg, Gynäkologie
| | - B Ataseven
- Kliniken Essen-Mitte (KEM) Evang. Huyssens-Stiftung/Knappschaft GmbH, Gynäkologie & Gynäkologische Onkologie
| | - S Schneider
- Kliniken Essen-Mitte (KEM) Evang. Huyssens-Stiftung/Knappschaft GmbH, Gynäkologie & Gynäkologische Onkologie
| | - T Baert
- Kliniken Essen-Mitte (KEM) Evang. Huyssens-Stiftung/Knappschaft GmbH, Gynäkologie & Gynäkologische Onkologie
| | - M Bommert
- Kliniken Essen-Mitte (KEM) Evang. Huyssens-Stiftung/Knappschaft GmbH, Gynäkologie & Gynäkologische Onkologie
| | - A Traut
- Kliniken Essen-Mitte (KEM) Evang. Huyssens-Stiftung/Knappschaft GmbH, Gynäkologie & Gynäkologische Onkologie
| | - A du Bois
- Kliniken Essen-Mitte (KEM) Evang. Huyssens-Stiftung/Knappschaft GmbH, Gynäkologische Onkologie
| | - P Harter
- Kliniken Essen-Mitte (KEM) Evang. Huyssens-Stiftung/Knappschaft GmbH, Gynäkologie & Gynäkologische Onkologie
| |
Collapse
|
23
|
Harter P, Sehouli J, Meier W, Reuss A, Hillemanns P, Hasenburg A, Hilpert F, Denschlag D, Burges A, Hanker L, Lampe B, Canzler U, Gropp-Meier M, du Bois A. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer – final analysis of AGO DESKTOP III/ENGOT- ov20. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - B Lampe
- Florence-Nightingale Krankenhaus
| | | | | | | |
Collapse
|
24
|
Heitz F, Ataseven B, Harter P, Bommert M, Concin N, Frindte J, Schneider S, du Bois A, Baert T. Erwartetes versus beobachtetes Ansprechen auf eine platin-haltige Chemotherapie nach poly(ADP-ribose) polymerase Inhibitor Behandlung bei Patientinnen mit rezidiviertem Ovarialkarzinom – eine retrospektive Analyse aus der Klinik für Gynäkologie und gynäkologischen Onkologie der Kliniken Essen-Mitte. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- F Heitz
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
- Department for Gynecology with the Center for Oncologic Surgery Charité Campus Virchow-Klinikum
| | - B Ataseven
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich
| | - P Harter
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
| | - M Bommert
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
| | - N Concin
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
- Department of Gynecology and Obstetrics; Innsbruck Medical Univeristy
| | - J Frindte
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
| | - S Schneider
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
| | - A du Bois
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
| | - T Baert
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
- Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven
| |
Collapse
|
25
|
Heitz F, Krämer P, Talhouk A, MA B, DS C, ES C, Scheunhage D, RF H, Senz J, Leung S, Hartkopf A, Krämer B, Brucker S, du Bois A, Harter P, FK K, Heublein S, Kommoss F, JN M, Singh N, Bosse T, Köbel M, MS A, Staebler A, Kommoss S. Anwendung der molekularen Risikostratifikation des Endometriums auf das endometrioide Ovarialkarzinom- eine retrospektive, internationale Multizenterstudie. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- F Heitz
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
| | - P Krämer
- Tuebingen University Hospital, Department of Women’s Health
- University of British Columbia, Department of Obstetrics and Gynecology
| | - A Talhouk
- University of British Columbia, Department of Obstetrics and Gynecology
- BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia’s Gynecological Cancer Research Team (OVCARE)
| | - Brett MA
- McMaster University, Department of Pathology and Molecular Medicine
| | - Chiu DS
- BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia’s Gynecological Cancer Research Team (OVCARE)
- BC Cancer Research Centre, Department of Molecular Oncology
| | - Cairns ES
- University of British Columbia, Department of Obstetrics and Gynecology
| | - D Scheunhage
- Leiden University Medical Centre (LUMC), Department of Pathology
| | - Hammond RF
- Barts Health National Health Service Trust, Department of Pathology
| | - J Senz
- BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia’s Gynecological Cancer Research Team (OVCARE)
- University of British Columbia, Department of Pathology and Laboratory Medicine
| | - S Leung
- BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia’s Gynecological Cancer Research Team (OVCARE)
- University of British Columbia, Department of Pathology and Laboratory Medicine
| | - A Hartkopf
- Tuebingen University Hospital, Department of Women’s Health
| | - B Krämer
- Tuebingen University Hospital, Department of Women’s Health
| | - S Brucker
- Tuebingen University Hospital, Department of Women’s Health
| | - A du Bois
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
| | - P Harter
- Kliniken Essen-Mitte, Klinik für Gynäkologie und gynäkologische Onkologie
| | - Kommoss FK
- Heidelberg University Hospital, Institute of Pathology
| | - S Heublein
- Heidelberg University Hospital, Heidelberg and National Center for Tumor Diseases, Department of Obstetrics and Gynecology
| | - F Kommoss
- Medizin Campus Bodensee, Institute of Pathology
| | - McAlpine JN
- University of British Columbia, Department of Obstetrics and Gynecology
- BC Cancer Research Centre, Department of Molecular Oncology
| | - N Singh
- Barts Health National Health Service Trust, Department of Pathology
| | - T Bosse
- Leiden University Medical Centre (LUMC), Department of Pathology
| | - M Köbel
- Department of Pathology and Laboratory Medicine, University of Calgary
| | - Anglesio MS
- University of British Columbia, Department of Obstetrics and Gynecology
- BC Cancer, Vancouver General Hospital, and University of British Columbia, British Columbia’s Gynecological Cancer Research Team (OVCARE)
| | - A Staebler
- University Hospital Tuebingen, Institute of Pathology and Neuropathology
| | - S Kommoss
- Tuebingen University Hospital, Department of Women’s Health
| |
Collapse
|
26
|
Grube M, Krämer P, Chiu D, Bosse T, Scheunhage D, Koebel M, Singh N, Manchanda R, Hammond R, Heitz F, Harter P, du Bois A, Ataseven B, Neudeck N, Beschorner C, Fischer A, Greif K, Krämer B, Brucker S, Talhouk A, Anglesio M, Staebler A, Kommoss S. Immunhistochemische Expression von L1CAM in endometrioiden Ovarialkarzinomen – Ein neuer prognostischer Marker? Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Grube
- Universitätsfrauenklinik Tübingen
| | - P Krämer
- Universitätsfrauenklinik Tübingen
| | - D Chiu
- Department of Obstetrics and Gynecology, University of British Columbia
| | - T Bosse
- Leiden University Medical Center
| | | | - M Koebel
- Department of Pathology and Laboratory Medicine, University of Calgary
| | - N Singh
- Dept of Cellular Pathology, BartsHealth NHS Trust
| | - R Manchanda
- Dept of Cellular Pathology, BartsHealth NHS Trust
| | - R Hammond
- Dept of Cellular Pathology, BartsHealth NHS Trust
| | | | | | | | | | - N Neudeck
- Institut für Pathologie, Universitätsklinikum Tübingen
| | - C Beschorner
- Institut für Pathologie, Universitätsklinikum Tübingen
| | - A Fischer
- Institut für Pathologie, Universitätsklinikum Tübingen
| | - K Greif
- Institut für Pathologie, Universitätsklinikum Tübingen
| | - B Krämer
- Universitätsfrauenklinik Tübingen
| | | | - A Talhouk
- Department of Obstetrics and Gynecology, University of British Columbia
| | - M Anglesio
- Department of Obstetrics and Gynecology, University of British Columbia
| | - A Staebler
- Institut für Pathologie, Universitätsklinikum Tübingen
| | | |
Collapse
|
27
|
Klar M, Matsuzaki S, Nusbaum DJ, Machida H, Nagase Y, Grubbs BH, Roman LD, Wright JD, Harter P, Matsuo K. Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Klar
- Frauenklinik des Universitätsklinikums Freiburg
| | - S Matsuzaki
- University of Southern California, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology
| | - DJ Nusbaum
- University of Southern California, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology
| | - H Machida
- Tokai University School of Medicine, Department of Obstetrics and Gynecology
| | - Y Nagase
- Osaka University School of Medicine, Department of Obstetrics and Gynecology
| | - BH Grubbs
- University of Southern California, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine
| | - LD Roman
- University of Southern California, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology
| | - JD Wright
- Columbia University College of Physicians and Surgeons, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology
| | - P Harter
- Kliniken Essen-Mitte (KEM) Evang. Huyssens-Stiftung/Knappschaft GmbH, Department of Gynecology and Gynecologic Oncology
| | - K Matsuo
- University of Southern California, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology
| |
Collapse
|
28
|
Schnelzer A, Harter P, Sehouli J, Canzler U, Marmé F, De Gregorio N, Buderath P, Lück HJ, Gropp-Meier M, Runnebaum I, Belau A, Renner S, Schmalfeldt B, El-Balat A, Burges A, Hillemanns P, Denschlag D, Bauerschlag D, Hanker L, Ray-Coquard I. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- A Schnelzer
- Universitätsfrauenklinik TU München Klinikum rechts der Isar
- RoMed Klinikum Rosenheim, Gynäkologie und Geburtshilfe
| | | | | | - U Canzler
- Universitätsfrauenklinik, Technische Universität Dresden
| | - F Marmé
- Universitätsfrauenklinik Heidelberg
- Universitätsfrauenklinik Mannheim
| | | | | | | | | | | | - A Belau
- Universitätsfrauenklinik Greifswald
- Gynäkologische Praxis
| | - S Renner
- Universitätsfrauenklinik Erlangen
| | | | | | - A Burges
- Universitätsfrauenklinik München Großhadern
| | | | | | | | | | | |
Collapse
|
29
|
Wimberger P, Sehouli J, Schmalfeldt B, Rau J, Thiel F, Hanker L, Marmé F, El-Balat A, De Gregorio N, Baumann K, Mahner S, Park-Simon TW, Meier W, Kommoss S, Bauerschlag D, Lück HJ, Kimmig R, Burges A, Schröder W, Jackisch C, Gropp-Meier M, Harter P, Pfisterer J. Carboplatin/PLD/Bevacizumab als neue Standardtherapieoption beim Ovarialkarzinomspätrezidiv – aktuelle Ergebnisse der AGO OVAR 2.21 Studie. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- P Wimberger
- Klinik und Poliklinik für Gynäkologie und Geburtshilfe der Technischen Universität Dresden
| | - J. Sehouli
- Charite Berlin, Klinik für Gynäkologie und Gynäkologische Onkologie – CVK
| | - B Schmalfeldt
- Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie
| | - J. Rau
- Philipps Universität Marburg, KKS
| | - F Thiel
- Universitätsklinikum Erlangen, Frauenklinik
| | - L Hanker
- Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Frauenklinik
| | - F Marmé
- Universitätsklinikum Mannheim, Frauenklinik
- Universitätsklinikum Heidelberg, NCT/Frauenklinik
| | - A El-Balat
- Universitätsklinikum Frankfurt, Klinik und Poliklinik für Gynäkologie und Geburtshilfe
| | | | - K Baumann
- Klinikum der Stadt Ludwigshafen am Rhein gemeinnützige GmbH, Frauenklinik
| | - S Mahner
- Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie
- LMU München Großhadern, Klinik und Poliklinik für Gynäkologie und Geburtshilfe
| | - TW Park-Simon
- Medizinische Hochschule Hannover, Klinik und Poliklinik für Gynäkologie und Geburtshilfe
| | - W Meier
- Universitätsklinikum Düsseldorf, Frauenklinik
- EVK Düsseldorf, Düsseldorf
| | - S Kommoss
- Universitätsklinikum Tübingen, Frauenklinik
| | - D Bauerschlag
- Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik und Poliklinik für Gynäkologie und Geburtshilfe
| | - HJ Lück
- Gynäkologisch Onkologische Praxis Hannover
| | - R Kimmig
- Universitätsklinikum Essen, Klinik und Poliklinik für Gynäkologie und Geburtshilfe
| | - A Burges
- LMU München Großhadern, Klinik und Poliklinik für Gynäkologie und Geburtshilfe
| | | | | | | | - P Harter
- Kliniken Essen-Mitte, Klinik für Gynäkologie und Gynäkologische Onkologie
| | | |
Collapse
|
30
|
Concin N, Gonzalez Martin A, Vergote I, Pignata S, Harter P, Patel M, Gunderson C, Wride K, Lepley D, Dusek R, Go J, Hurley S, Cameron T, Hamilton E. 885TiP LIO-1: A phase II study of lucitanib + nivolumab in patients (pts) with gynaecological tumours (CO-3810-101; NCT04042116; ENGOT-GYN3/AGO/LIO). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2091] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
31
|
Hasenburg A, Plett H, Krämer B, Braicu E, Czogalla B, Bossart M, Singer S, Mayr D, Staebler A, du Bois A, Kommoss S, Link T, Burges A, Heitz F, Keul J, Trillsch F, Harter P, Wimberger P, Buderath P, Klar M. 876P The effect of surgical techniques on sexuality and global quality of life (Qol) in women with ovarian germ cell (OGCT) and sex cord stromal tumours (SCST): An analysis of the AGO-CORSETT database. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
32
|
Lecuru F, du Bois A, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Jensen P, Selle F, Guyon F, Pomel C, Zang R, Avall-Lundqvist E, Kim JW, Ponce J, Raspagliesi F, Sadaf GM, Reinthaller A, Harter P. 816MO AGO DESKTOP III/ENGOT OV20: Impact of surgical characteristics and time to first subsequent therapy (TFST). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.955] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
33
|
Jueckstock J, Fuerst S, Bommert M, Harter P, Prieske K, Eulenburg C, Hilpert F, deGregorio N, Iborra S, Sehouli J, Ignatov A, Hillemanns P, Jaeger A, Strauss HG, Baumann K, Thiel F, Mustea A, Meier W, Wimberger P, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Woelber L, Mahner S. Bedeutung der pelvinen Lymphonodektomie beim Plattenepithelkarzinom der Vulva (VSCC) – Subgruppenanalyse der AGO-CaRE-1 Studie. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1713981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- J Jueckstock
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München
| | - S Fuerst
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München
| | - M Bommert
- Klinik für Gynäkologie & Gynäkologische Onkologie, Evang. Kliniken Essen-Mitte, Essen
| | - P Harter
- Klinik für Gynäkologie & Gynäkologische Onkologie, Evang. Kliniken Essen-Mitte, Essen
| | - K Prieske
- Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - C Eulenburg
- Institut für Medizinische Biometrie und Epidemiologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - F Hilpert
- Onkologisches Kompetenzzentrum, Krankenhaus Jerusalem, Hamburg
| | - N deGregorio
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Ulm
| | - S Iborra
- Klinik für Gynäkologie und Geburtsmedizin, Uniklinik RWTH Aachen
| | - J Sehouli
- Klinik für Gynäkologie, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin
| | - A Ignatov
- Universitätsklinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Magdeburg
| | - P Hillemanns
- Klinik für Frauenheilkunde und Geburtshilfe, Medizinische Hochschule Hannover
| | - A Jaeger
- Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - H-G Strauss
- Universitätsklinik und Poliklinik für Gynäkologie, Halle
| | - K Baumann
- Frauenklinik am Klinikum Ludwigshafen
| | - F Thiel
- Frauenklinik mit Gynäkologie und Geburtshilfe, Alb Fils Kliniken, Klinik am Eichert, Göppingen
| | - A Mustea
- Zentrum für Geburtshilfe und Frauenheilkunde, Universitätsklinikum Bonn
| | - W Meier
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Düsseldorf
| | - P Wimberger
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Technische Universität Dresden
| | - L Hanker
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Lübeck
| | - B Schmalfeldt
- Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - U Canzler
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Technische Universität Dresden
| | - T Fehm
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Düsseldorf
| | - A Luyten
- Frauenklinik, Klinikum Wolfsburg
| | - M Hellriegel
- Klinik für Gynäkologie und Geburtshilfe, Universitätsmedizin Göttingen
| | - J Kosse
- Klinik für Gynäkologie und Geburtshilfe, Sana Klinikum Offenbach
| | - C Heiss
- Frauenklinik mit Gynäkologie und Geburtshilfe, Alb Fils Kliniken, Klinik am Eichert, Göppingen
| | - P Hantschmann
- Klinik für Gynäkologie und Geburtshilfe, Kreiskliniken Altötting-Burghausen, Altötting
| | - P Mallmann
- Klinik für Frauenheilkunde und Geburtshilfe, Uniklinik Köln
| | - B Tanner
- Klinik für Gynäkologie und Geburtshilfe, Oberhavel Klinik Oranienburg
| | | | - L Woelber
- Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München
| |
Collapse
|
34
|
Drott U, Harter P, Burkhardt H, Mittelbronn M. AB1237 Diagnostic value of proteasomal and autophagic markers in muscular diseases. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.5897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Deficient cellular degradation pathways such as autophagy and the ubiquitin proteasome system (UPS) show a correlation with the onset of neurodegenerative diseases. Especially immune-mediated inflammatory myopathies often show therapy-resistant phenotypes with medical need for further understanding of pathogenesis und possible treatment.Objectives:The aim of this work was to study an association of these two degradation pathways in a large group of different muscle entities and to examine a possible influence in the pathogenesis of the investigated muscle diseases. Furthermore, a potential benefit in diagnostics was studied using factors such as ubiquitin, p62, NBR1 and LC3 and their role as adapter molecules.Methods:We examined ubiquitin, p62, NBR1 and LC3 on muscle biopsies from patients with the diagnosis of s-IBM, dermato- and polymyositis, muscular dystrophy, neurogenic atrophy, myotonic dystrophy type II (PROMM) and metabolic myopathies such as Pompe and McArdle disease. Immunohistochemical single and double stainings as well as immunofluorescence stainings were performed on cryosections. Furthermore, Western blot analysis was performed. The use of a histological score, defined as the product of the frequency of positive fibres and staining intensity, was used to investigate possible differences between the diseases in the expression of the investigated factors.Results:Especially in s-IBM, myofibrillar myopathies and Pompe disease, proteasomal and autophagic markers were detected. On the other hand, neurogenic atrophy, McArdle disease and the majority of the myotonic dystrophies type II showed no positive signals, except for p62, which was detected especially in internalized nuclei and regenerative fibres. Overall, in all entities in regenerative and necrotic as well as in atrophic fibres, a positive staining for ubiquitin, p62, NBR1 and LC3 could be shown. Dermatomyositis showed a moderate immunoreactivity for p62 and NBR1 in the area of the perifascicular atrophy. Polymyositis showed a strong endomysial reaction in the area of the attacked muscle fibres, especially in the area of the lymphocytic infiltrates. The histological score showed that ubiquitin was significantly higher in s-IBM than in polymyositis. NBR1 was significantly higher in s-IBM than in dermatomyositis and muscular dystrophies. LC3 and p62 showed a significantly higher level in s-IBM as compared to dermatomyositis and polymyositis. Except for NBR1, a positive correlation of autophagic and proteasomal markers was shown in dermatomyositis. There was also a positive correlation between LC3 and ubiquitin in polymyositis. Using multivariate analysis and recursive partitioning, we could show a predictability of the diagnosis of s-IBM with a LC3 score above 3. On the other hand, a value below 3 excluded the diagnosis of s-IBM.Conclusion:In particular, s-IBM, myofibrillar myopathies and Pompe disease showed a possible involvement disturbed proteasomal and autophagic degradation pathways in their pathogenesis. In addition, p62 and NBR1 seemed to have an important role in the immune response. Furthermore, the altered autophagic and proteasomal degradation pathways may be involved in ageing processes, sarcopenia and disease. In particular, LC3 seems to be suitable as a screening marker to recognize an idiopathic inflammatory myopathy. The other markers, such as p62, LC3, and NBR1, would be able to distinguish between the subgroups of idiopathic inflammatory myopathies. Therefore, LC3 could be included as a marker in the routine of neuropathological diagnostics. Further studies are needed to fully understand the role of proteasomal and autophagic factors in possible immune suppressive and immune modulatory therapies and to assess possible side effects.Disclosure of Interests:Ulrich Drott: None declared, Patrick Harter: None declared, Harald Burkhardt Grant/research support from: Pfizer, Roche, Abbvie, Consultant of: Sanofi, Pfizer, Roche, Abbvie, Boehringer Ingelheim, UCB, Eli Lilly, Chugai, Bristol Myer Scripps, Janssen, and Novartis, Speakers bureau: Sanofi, Pfizer, Roche, Abbvie, Boehringer Ingelheim, UCB, Eli Lilly, Chugai, Bristol Myer Scripps, Janssen, and Novartis, Michel Mittelbronn: None declared
Collapse
|
35
|
Fujiwara K, Harter P, Leary A, Perol D, Pignata S, González-Martín A, Petru E, van Nieuwenhuysen E, Colombo N, Mäenpää J, Selle F, de Gregorio N, Lorusso D, Guerra Alia E, Lefeuvre-Plesse C, Buderath P, Lortholary A, Burges A, Pujade-Lauraine E, Ray-Coquard I. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz446.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Sevelda P, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Alia EMG, Lefeuvre-Plesse C, Canzler U, Lortholary A, Marmé F, Pujade-Lauraine E, Harter P. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.053] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Fürst S, Lück HJ, Schnelzer A, Sehouli J, Harter P, Ray-Coquard I. Alienor/Engot-Ov7 – Eine randomisierte Phase-II-Studie bei rezidiviertem Keimstrangstroma-Tumor (SCT) mit Bevacizumab (Bev) in Kombination mit wöchentlichem Paclitaxel versus wöchentlichem Paclitaxel allein (wPac). Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1693906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Affiliation(s)
- S Fürst
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Ludwig-Maximilians-Universität München
| | - HJ Lück
- Gynäkologisch-Onkologische Praxis am Pelikanplatz, Hannover
| | - A Schnelzer
- Klinik und Poliklinik für Frauenheilkunde, Technische Universität München & Klinik für Gynäkologie und Geburtshilfe, RoMed Klinikum, Rosenheim
| | - J Sehouli
- Campus Virchow Klinikum, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Universitätsmedizin Berlin Charité
| | - P Harter
- Klinik für Gynäkologie und gynäkologische Onkologie, Evangelische Kliniken Essen-Mitte (KEM)
| | - I Ray-Coquard
- Medical Oncology, Centre Leon Berard & Université Claude Bernard Lyon Est
| |
Collapse
|
38
|
de Gregorio N, Park-Simon TW, Meier W, Kommoss S, Hilpert F, Lück HJ, Baumann K, Harter P, Sehouli J, Canzler U, Schmalfeldt B, Hein A, Hanker L, Marmé F, El-Balat A, Mahner S, Kimmig R, Burges A, Schröder W, Jackisch C, Gropp-Meier M, Fehm T, Hasenburg A, Denschlag D, Belau A, Pfisterer J. Carboplatin/Caelyx/Bevacizumab vs. Carboplatin/Gemcitabine/Bevacizumab beim platinsensiblen Ovarialkarzinomrezidiv: Ergebnisse der prospektiv-randomisierten Phase III AGO-OVAR 2.21 Studie. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1693899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Affiliation(s)
| | | | - W Meier
- Evangelisches Krankenhaus Düsseldorf
| | | | - F Hilpert
- Universitätsklinikum Schleswig-Holstein, Campus Kiel
| | - HJ Lück
- Gynäkologisch-Onkologische Praxis Hannover
| | | | | | | | - U Canzler
- Universitätsklinikum an der TU Dresden
| | | | - A Hein
- Universitäts-Frauenklinik Erlangen
| | | | - F Marmé
- Universitätsklinikum Heidelberg
| | | | | | | | | | | | | | | | - T Fehm
- Universitätsklinikum Düsseldorf
| | - A Hasenburg
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Mainz
| | | | - A Belau
- Universitätsmedizin Greifswald
| | | |
Collapse
|
39
|
Mahner S, du Bois A, Pfisterer J, Hilpert F, Sehouli J, Lamparter C, Kerkmann M, Harter P. Behandlungsqualität des Ovarialkarzinoms in Deutschland: Aktuelle Ergebnisse des Qualitätssicherungsprogramms QS OVAR. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1693901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Affiliation(s)
- S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsfrauenklinik München
| | - A du Bois
- Klinik für Gynäkologie & Gyn. Onkologie, Kliniken Essen-Mitte, Essen
| | | | - F Hilpert
- Onkologisches Therapiezentrum Krankenhaus Jerusalem, Hamburg
| | | | | | | | - P Harter
- Klinik für Gynäkologie & Gyn. Onkologie, Kliniken Essen-Mitte, Essen
| |
Collapse
|
40
|
Runnebaum IB, Hilpert F, du Bois A, Harter P. Therapy of ovarian cancer (OC) in Germany – Treatment characteristics QS OVAR 2016. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1692077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Affiliation(s)
- IB Runnebaum
- Klinik und Poliklinik für Frauenheilkunde und Fortpflanzungsmedizin, Universitätsklinikum Jena
| | - F Hilpert
- Onkologisches Therapiezentrum Krankenhaus Jerusalem, Hamburg
| | - A du Bois
- Klinik für Gynäkologie & Gyn. Onkologie, Kliniken Essen-Mitte, Essen
| | - P Harter
- Klinik für Gynäkologie & Gyn. Onkologie, Kliniken Essen-Mitte, Essen
| |
Collapse
|
41
|
Kranawetter M, Grimm C, Ataseven B, Schneider S, Alesino P, Riss S, Prader S, Walz M, Harpain F, Stift A, Heitz F, Polterauer S, Kölbl H, Reinthaller A, Bartl T, Harter P, du Bois A. „Low Anterior Resection Syndrome“ (LARS) bei Patientinnen mit epithelialem Ovarialkarzinom. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1681991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Affiliation(s)
- M Kranawetter
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Wien
| | - C Grimm
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Wien
| | - B Ataseven
- Klinik für Gynäkologie und gynäkologische Onkologie, Kliniken Essen Mitte
| | - S Schneider
- Klinik für Gynäkologie und gynäkologische Onkologie, Kliniken Essen Mitte
| | - P Alesino
- Abteilung für Chirugie, Kliniken Essen Mitte
| | - S Riss
- Universitätsklinik für Chirurgie, Medizinische Universität Wien
| | - S Prader
- Klinik für Gynäkologie und gynäkologische Onkologie, Kliniken Essen Mitte
| | - M Walz
- Abteilung für Chirugie, Kliniken Essen Mitte
| | - F Harpain
- Universitätsklinik für Chirurgie, Medizinische Universität Wien
| | - A Stift
- Universitätsklinik für Chirurgie, Medizinische Universität Wien
| | - F Heitz
- Klinik für Gynäkologie und gynäkologische Onkologie, Kliniken Essen Mitte
| | - S Polterauer
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Wien
| | - H Kölbl
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Wien
| | - A Reinthaller
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Wien
| | - T Bartl
- Universitätsklinik für Frauenheilkunde, Medizinische Universität Wien
| | - P Harter
- Klinik für Gynäkologie und gynäkologische Onkologie, Kliniken Essen Mitte
| | - A du Bois
- Klinik für Gynäkologie und gynäkologische Onkologie, Kliniken Essen Mitte
| |
Collapse
|
42
|
Heitz F, Harter P, Åvall-Lundqvist E, Reuss A, Pautier P, Cormio G, Colombo N, Reinthaller A, Vergote I, Poveda A, Ottevanger P, Hanker L, Leminen A, Alexandre J, Canzler U, Sehouli J, Herrstedt J, Fiane B, Merger M, du Bois A. Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. Gynecol Oncol 2019; 152:235-242. [DOI: 10.1016/j.ygyno.2018.11.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Revised: 10/30/2018] [Accepted: 11/06/2018] [Indexed: 10/27/2022]
|
43
|
Ehmann S, du Bois A, Harter P, Heitz F, Prader S, Traut A, Pauly N, Heikaus S, Ataseven B. Altersabhängiger Vergleich von histologischem Tumortyp und Stadienverteilung bei Patientinnen mit primärem epithelialem Ovarialkarzinom. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- S Ehmann
- Kliniken Essen-Mitte (KEM), Gynäkologie und Gynäkologische Onkologie, Essen, Deutschland
| | - A du Bois
- Kliniken Essen-Mitte (KEM), Gynäkologie und Gynäkologische Onkologie, Essen, Deutschland
| | - P Harter
- Kliniken Essen-Mitte (KEM), Gynäkologie und Gynäkologische Onkologie, Essen, Deutschland
| | - F Heitz
- Kliniken Essen-Mitte (KEM), Gynäkologie und Gynäkologische Onkologie, Essen, Deutschland
| | - S Prader
- Kliniken Essen-Mitte (KEM), Gynäkologie und Gynäkologische Onkologie, Essen, Deutschland
| | - A Traut
- Kliniken Essen-Mitte (KEM), Gynäkologie und Gynäkologische Onkologie, Essen, Deutschland
| | - N Pauly
- Kliniken Essen-Mitte (KEM), Gynäkologie und Gynäkologische Onkologie, Essen, Deutschland
| | - S Heikaus
- Zentrum für Pathologie Essen-Mitte, Essen, Deutschland
| | - B Ataseven
- Kliniken Essen-Mitte (KEM), Gynäkologie und Gynäkologische Onkologie, Essen, Deutschland
| |
Collapse
|
44
|
Harter P, Prader S, Ataseven B, Heitz F, Alesina P, Gröben H, Traut A, du Bois A. Survival of patients with advanced ovarian cancer in a specialized center from 1998 – 2016. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- P Harter
- Kliniken Essen-Mitte, Gynecology & Gynecologic Oncology, Essen, Deutschland
| | - S Prader
- Kliniken Essen-Mitte, Gynecology & Gynecologic Oncology, Essen, Deutschland
| | - B Ataseven
- Kliniken Essen-Mitte, Gynecology & Gynecologic Oncology, Essen, Deutschland
| | - F Heitz
- Kliniken Essen-Mitte, Gynecology & Gynecologic Oncology, Essen, Deutschland
| | - P Alesina
- Kliniken Essen-Mitte, Visceral Surgery, Essen, Deutschland
| | - H Gröben
- Kliniken Essen-Mitte, Anesthesiology, Essen, Deutschland
| | - A Traut
- Kliniken Essen-Mitte, Gynecology & Gynecologic Oncology, Essen, Deutschland
| | - A du Bois
- Kliniken Essen-Mitte, Gynecology & Gynecologic Oncology, Essen, Deutschland
| |
Collapse
|
45
|
Hanker LC, Heitz F, Park-Simon TW, Gropp-Meier M, Ataseven B, Pujade-Lauraine E, Harter P. Tolerability of olaparib tablets as maintenance therapy in patients with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2/AGO-OVAR2.23 trial. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- LC Hanker
- Universitätsklinikum Schleswig-Holstein Campus Lübeck, Klinik für Gynäkologie und Geburtshilfe, Lübeck, Deutschland
| | - F Heitz
- Kliniken Essen-Mitte (KEM), Evang. Huyssens-Stiftung/Knappschaft GmbH, Klinik für Gynäkologie und gyn. Onkologie, Essen, Deutschland
| | - TW Park-Simon
- Medizinische Hochschule Hannover, Klinik für Frauenheilkunde und Geburtshilfe, Hannover, Deutschland
| | - M Gropp-Meier
- Oberschwabenklinik, Krankenhaus St. Elisbeth, Frauenklinik, Ravensburg, Deutschland
| | - B Ataseven
- Kliniken Essen-Mitte (KEM), Evang. Huyssens-Stiftung/Knappschaft GmbH, Klinik für Gynäkologie und gyn. Onkologie, Essen, Deutschland
| | - E Pujade-Lauraine
- Université Paris Descartes, Medical Oncology Department, Paris, Frankreich
| | - P Harter
- Kliniken Essen-Mitte (KEM), Evang. Huyssens-Stiftung/Knappschaft GmbH, Klinik für Gynäkologie und gyn. Onkologie, Essen, Deutschland
| |
Collapse
|
46
|
Trillsch F, du Bois A, Sehouli J, Canzler U, Marmé F, Hilpert F, Lück HJ, Meier W, Emons G, Heubner ML, Harter P, Reinthaller A, Mirza MR, Oza A, Mahner S. Lebensqualität unter Niraparib-Erhaltungstherapie bei Patientinnen mit rezidiviertem Ovarialkarzinom: Ergebnisse der AGO-OVAR 2.22-Studie (ENGOT-OV16/NOVA). Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- F Trillsch
- Klinikum der Universität München, LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
| | - A du Bois
- Kliniken Essen-Mitte (KEM), Evang. Huyssens-Stiftung/Knappschaft GmbH, Klinik für Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - J Sehouli
- Universitätsmedizin Berlin Charité, Campus Virchow Klinikum, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Berlin, Deutschland
| | - U Canzler
- Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Dresden, Deutschland
| | - F Marmé
- Nationales Centrum für Tumorerkrankungen, Universitätsfrauenklinik, Heidelberg, Deutschland
| | - F Hilpert
- Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Gynäkologie und Geburtshilfe, Kiel, Deutschland
- Onkologisches Therapiezentrum am Krankenhaus Jerusalem, Hamburg, Deutschland
| | - HJ Lück
- Gynäkologisch-Onkologische Praxis am Pelikanplatz, Hannover, Deutschland
| | - W Meier
- Evangelisches Krankenhaus, Frauenklinik, Düsseldorf, Deutschland
| | - G Emons
- Universitätsmedizin Göttingen, Klinik für Gynäkologie und Geburtshilfe, Göttingen, Deutschland
| | - ML Heubner
- Universitätsklinik für Frauenheilkunde und Geburtshilfe, Essen, Deutschland
- Kantonsspital Baden AG, Department Frauen und Kinder, Baden, Schweiz
| | - P Harter
- Kliniken Essen-Mitte (KEM), Evang. Huyssens-Stiftung/Knappschaft GmbH, Klinik für Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - A Reinthaller
- Universitätsfrauenklinik Wien, Abteilung für Allgemeine Gynäkologie und Gynäkologische Onkologie, Wien, Österreich
| | - MR Mirza
- Ringshospitalet – Copenhagen University Hospital, Department of Oncology, Kopenhagen, Dänemark
| | - A Oza
- Princess Margaret Cancer Centre, Toronto, Kanada
| | - S Mahner
- Klinikum der Universität München, LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
| |
Collapse
|
47
|
Alavi S, Harter P, Richter R, Keller M, Oskay-Özcelik G, Mustea A, Schmalfeldt B, Wimberger P, Trillsch F, Mahner S, Klar M, Wagner U, Chekerov R, du Bois A, Sehouli J. MONITOR VII – Behandlungsstrategie beim Low-grade Ovarialkarzinom. Eine deutschlandweite Umfrage der Charité – Berlin und Kliniken Essen Mitte mit Unterstützung der NOGGO und AGO. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1670991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- S Alavi
- Charité – Universitätsmedizin Berlin, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Berlin, Deutschland
| | - P Harter
- Kliniken Essen Mitte, Essen, Deutschland
| | - R Richter
- Charité – Universitätsmedizin Berlin, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Berlin, Deutschland
| | - M Keller
- Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie, Berlin, Deutschland
| | - G Oskay-Özcelik
- Charité – Universitätsmedizin Berlin, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Berlin, Deutschland
| | - A Mustea
- Universitätsmedizin Greifswald, Greifswald, Deutschland
| | - B Schmalfeldt
- Universitätsklinikum Eppendorf, Hamburg, Deutschland
| | - P Wimberger
- Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Deutschland
| | - F Trillsch
- Klinikum der Ludwig-Maximilians-Universität München, München, Deutschland
| | - S Mahner
- Klinikum der Ludwig-Maximilians-Universität München, München, Deutschland
| | - M Klar
- Universitätsklinik Freiburg, Freiburg, Deutschland
| | - U Wagner
- Philipps-Universität Marburg, Marburg, Deutschland
| | - R Chekerov
- Charité – Universitätsmedizin Berlin, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Berlin, Deutschland
| | - A du Bois
- Kliniken Essen Mitte, Essen, Deutschland
| | - J Sehouli
- Charité – Universitätsmedizin Berlin, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Berlin, Deutschland
| |
Collapse
|
48
|
Plett H, Harter P, Prader S, Ataseven B, Heitz F, Bommert M, Schneider S, Alesina PF, Traut A, du Bois A. Role of primary surgery for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- H Plett
- Kliniken-Essen-Mitte, Gynäkologische Onkologie, Essen, Deutschland
| | - P Harter
- Kliniken-Essen-Mitte, Gynäkologische Onkologie, Essen, Deutschland
| | - S Prader
- Kliniken-Essen-Mitte, Gynäkologische Onkologie, Essen, Deutschland
| | - B Ataseven
- Kliniken-Essen-Mitte, Gynäkologische Onkologie, Essen, Deutschland
| | - F Heitz
- Kliniken-Essen-Mitte, Gynäkologische Onkologie, Essen, Deutschland
| | - M Bommert
- Kliniken-Essen-Mitte, Gynäkologische Onkologie, Essen, Deutschland
| | - S Schneider
- Kliniken-Essen-Mitte, Gynäkologische Onkologie, Essen, Deutschland
| | - PF Alesina
- Kliniken-Essen-Mitte, Chirurgie, Essen, Deutschland
| | - A Traut
- Kliniken-Essen-Mitte, Gynäkologische Onkologie, Essen, Deutschland
| | - A du Bois
- Kliniken-Essen-Mitte, Gynäkologische Onkologie, Essen, Deutschland
| |
Collapse
|
49
|
Marmé F, du Bois A, Sehouli J, Canzler U, Hilpert F, Lück HJ, Meier W, Emons G, Heubner ML, Wölber L, Harter P, Marth C, Mirza MR, Mahner S. Sicherheit und Wirksamkeit von Niraparib bei älteren Patientinnen mit rezidiviertem Ovarialkarzinom: eine Subgruppenanalyse der AGO Ovar 2.22 (ENGOT-OV16/NOVA) Phase III Studie. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- F Marmé
- Universitärtsklinikum Heidelberg, Nationales Centrum für TUmorerkrankungen; Sektion Gynäkologische Onkologie, Heidelberg, Deutschland
| | - A du Bois
- Kliniken Essen Mitte, Evang. Huyssens-Stiftung/Knappschaft GmbH, Klinik für Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - J Sehouli
- Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Berlin, Deutschland
| | - U Canzler
- Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Dresden, Deutschland
| | - F Hilpert
- Universitätklinikum Schleswig-Holstein, Campus Kiel, Klinik für Gynäkologie und Geburtshilfe, Kiel, Deutschland
- Onkologisches Therapiezentrum Krankenhaus Jerusalem, Hamburg, Deutschland
| | - HJ Lück
- Gynäkologisch-Onkologische Praxis am Pelikanplatz, Hannover, Germany, Hannover, Deutschland
| | - W Meier
- Universitätsfrauenklinik Düsseldorf, Düsseldorf, Deutschland
| | - G Emons
- Universitätsmedizin Göttingen, Klinik für Gynäkologie und Geburtshilfe, Göttingen, Deutschland
| | - ML Heubner
- Kliniken Essen-Mitte (KEM), Evang. Huyssens-Stiftung/Knappschaft GmbH, Klinik für Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
- Kantonsspital Baden AG, Department Frauen und Kinder, Baden, Schweiz
| | - L Wölber
- Universitätklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland
| | - P Harter
- Kliniken Essen-Mitte (KEM), Evang. Huyssens-Stiftung/Knappschaft GmbH, Klinik für Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - C Marth
- Medizinische Universität Innsbruck, Univ. Klinik für Frauenheilkunde, Innsbruck, Österreich
| | - MR Mirza
- Ringshospitalet – Copenhagen University Hospital, Department of Oncology, Copenhagen, Dänemark
| | - S Mahner
- Klinikum der Universität München, LMU, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
| |
Collapse
|
50
|
Frindte J, Ataseven B, Harter P, Göke G, Podkowinkski J, Vogt C, Bluni V, Vincent M, Traut A, Heitz F, Kümmel S, Prader S, Bommert M, Schneider S, du Bois A. Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- J Frindte
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - B Ataseven
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - P Harter
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - G Göke
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - J Podkowinkski
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - C Vogt
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - V Bluni
- Kliniken Essen Mitte, Senologie/Interdisziplinäres Brustzentrum, Essen, Deutschland
| | - M Vincent
- Kliniken Essen Mitte, Senologie/Interdisziplinäres Brustzentrum, Essen, Deutschland
| | - A Traut
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - F Heitz
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - S Kümmel
- Kliniken Essen Mitte, Senologie/Interdisziplinäres Brustzentrum, Essen, Deutschland
| | - S Prader
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - M Bommert
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - S Schneider
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| | - A du Bois
- Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie, Essen, Deutschland
| |
Collapse
|